Livalo News and Research

RSS
Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Pitavastatin may reduce risk of heart attack, stroke and death in patients with high cholesterol

Pitavastatin may reduce risk of heart attack, stroke and death in patients with high cholesterol

Lilly, Kowa announce results from PREVAIL U.S. study

Lilly, Kowa announce results from PREVAIL U.S. study

Kowa announces data of LIVALO vs. Crestor on pharmacodynamics of warfarin

Kowa announces data of LIVALO vs. Crestor on pharmacodynamics of warfarin

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Cipher Pharmaceuticals second-quarter net revenues increase to $2.2 million

Cipher Pharmaceuticals second-quarter net revenues increase to $2.2 million

BBD reports analyze effectiveness and safety of statin use

BBD reports analyze effectiveness and safety of statin use

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

Cipher Pharmaceuticals' first-quarter total revenue up 52%

Cipher Pharmaceuticals' first-quarter total revenue up 52%

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

LIVALO statin effective than simvastatin in reducing lipid levels

LIVALO statin effective than simvastatin in reducing lipid levels

High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO

High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO

FDA approves Livalo (pitavastatin), a new cholesterol-lowering drug

FDA approves Livalo (pitavastatin), a new cholesterol-lowering drug